IBS-C Drug Market to Reach $3.08 Billion by 2035

The IBS-C drug market was valued at $2.30 billion in 2025 and is projected to reach $3.08 billion by 2035, registering a CAGR of 3.1% over the forecast period from 2026 to 2035. Recent epidemiological research indicates that IBS with constipation (IBS?C) represents a substantial portion of diagnosed IBS cases globally, supporting strong demand for targeted therapies in the IBS?C drug market. A comprehensive meta?analysis using the latest Rome IV criteria found that IBS?C accounted for approximately 34.2% of all IBS cases, reflecting a significant patient population requiring ongoing pharmacological intervention. This high subtype prevalence underscores the need for both established prescription drugs like linaclotide and lubiprostone, as well as evolving treatment approaches, which collectively reinforce market growth by expanding the addressable patient base and driving therapeutic innovation. The prevalence data also highlight why leading pharmaceutical companies continue to invest in clinical development and educational outreach to optimize management of IBS?C across diverse regions.

Browse the full report description of “Irritable Bowel Syndrome with Constipation (IBS-C) Drug Market Size, Share & Trends Analysis Report by Drug Type (Lubiprostone, Linaclotide, Stimulant Laxatives, Osmotic Laxatives, and Others), and by Prescription Type (Prescription Drugs, and Over-the-Counter Drugs), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/ibs-c-drug-market

In addition, broader IBS prevalence research supports this focus: global functional gastrointestinal disorder data suggest that roughly 33.2% of adults globally experience some form of functional bowel disorder, with functional constipation and IBS contributing significantly to this overall burden, which in turn elevates patient demand for effective IBS?C drugs.

Key findings supporting this trend:

• A global meta?analysis reported IBS?C accounting for ~34.2% of all IBS cases using Rome IV criteria.
• Overall, IBS prevalence remains high (~14%) when standardized diagnostic criteria are applied.
• Functional bowel disorders affect about one?third of adults globally, emphasizing the widespread need for treatment.
• Prevalence estimates vary by diagnostic criteria, with Rome IV detecting higher IBS?C representation.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • Drug Type
  • Prescription Type
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape – AbbVie Inc., Ardelyx, Inc., Ironwood Pharmaceuticals, Inc., Novartis AG, Takeda Pharmaceutical Company Ltd., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Irritable Bowel Syndrome with Constipation (IBS-C) Drug Market Report Segment

By Drug Type

• Lubiprostone
• Linaclotide
• Stimulant Laxatives
• Osmotic Laxatives
• Others

By Prescription Type

• Prescription Drugs
• Over-the-Counter Drugs

Global Irritable Bowel Syndrome with Constipation (IBS-C) Drug Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/ibs-c-drug-market